GDS Wealth Management Has $11.61 Million Holdings in Natera, Inc. $NTRA

GDS Wealth Management lifted its holdings in shares of Natera, Inc. (NASDAQ:NTRA) by 11.1% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 72,117 shares of the medical research company’s stock after purchasing an additional 7,177 shares during the period. GDS Wealth Management owned 0.05% of Natera worth $11,609,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of NTRA. iA Global Asset Management Inc. acquired a new stake in shares of Natera in the 3rd quarter worth about $1,072,000. Covestor Ltd raised its stake in shares of Natera by 45.8% in the third quarter. Covestor Ltd now owns 850 shares of the medical research company’s stock valued at $137,000 after buying an additional 267 shares during the period. Aubrey Capital Management Ltd bought a new stake in shares of Natera in the third quarter valued at approximately $2,607,000. Rakuten Investment Management Inc. purchased a new stake in shares of Natera during the 3rd quarter valued at approximately $34,096,000. Finally, Universal Beteiligungs und Servicegesellschaft mbH lifted its holdings in Natera by 15.9% during the 3rd quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 139,802 shares of the medical research company’s stock worth $22,504,000 after purchasing an additional 19,166 shares in the last quarter. 99.90% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Natera

In other Natera news, CEO Steven Leonard Chapman sold 1,590 shares of the stock in a transaction that occurred on Wednesday, January 21st. The stock was sold at an average price of $235.00, for a total transaction of $373,650.00. Following the transaction, the chief executive officer owned 219,150 shares in the company, valued at approximately $51,500,250. This represents a 0.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Michael Burkes Brophy sold 37,175 shares of the company’s stock in a transaction on Wednesday, January 21st. The stock was sold at an average price of $242.54, for a total transaction of $9,016,424.50. Following the transaction, the chief financial officer owned 64,123 shares of the company’s stock, valued at $15,552,392.42. This represents a 36.70% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 514,562 shares of company stock valued at $114,292,421. 5.63% of the stock is currently owned by insiders.

Natera Stock Down 0.5%

Natera stock opened at $241.58 on Friday. The company has a market cap of $33.42 billion, a PE ratio of -105.49 and a beta of 1.62. The company’s 50-day moving average price is $234.18 and its 200-day moving average price is $191.40. Natera, Inc. has a twelve month low of $125.38 and a twelve month high of $256.36.

Natera (NASDAQ:NTRA) last announced its quarterly earnings data on Friday, November 7th. The medical research company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.25). Natera had a negative net margin of 14.61% and a negative return on equity of 25.07%. The business had revenue of $592.18 million during the quarter, compared to the consensus estimate of $514.55 million. During the same period last year, the company earned ($0.26) EPS. The business’s revenue was up 34.7% compared to the same quarter last year. As a group, sell-side analysts expect that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Trending Headlines about Natera

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Peer‑reviewed clinical validation: Natera published clinical validation of its Latitude™ tissue‑free MRD test in colorectal cancer, boosting the credibility of a higher‑value oncology product that could support future revenue and reimbursement expansion. Clinical validation article
• Positive Sentiment: Analyst support: Multiple sell‑side firms have raised price targets and the consensus remains a “Moderate Buy” with an implied target around the mid‑$200s, providing medium‑term bullish backing for the stock.
• Neutral Sentiment: Fund positioning note: A Voya MidCap Opportunities investor letter and related coverage highlight that lack of exposure to Natera hurt that fund’s Q4 performance — a sign NTRA was a notable outperformer for some mid‑cap portfolios but not a direct company catalyst. Voya fund note
• Neutral Sentiment: Mixed fundamentals & ownership: Recent quarter showed strong revenue growth (~35% YoY) but continued GAAP losses; institutional ownership is extremely high (~99.9%), which reduces free float and can both support and cap volatility depending on flows.
• Negative Sentiment: Clustered insider selling — material: CEO Steven Chapman, CFO Michael Burkes Brophy and other insiders executed large sales on Jan. 20–21 (CEO sale ~71.9k shares; CFO sales totaling ~61k+ shares across days), representing sizable reductions in holdings and increasing perceived near‑term supply pressure. CEO Form 4
• Negative Sentiment: Additional insider sales: Multiple smaller insider transactions (e.g., Solomon Moshkevich) were also reported, reinforcing the market perception of insider liquidity taking and adding downward pressure. InsiderTrades coverage

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on NTRA. Guggenheim lifted their price objective on Natera from $230.00 to $270.00 and gave the company a “buy” rating in a research note on Monday, January 5th. Barclays increased their price objective on Natera from $230.00 to $270.00 and gave the company an “overweight” rating in a research note on Monday, December 15th. Zacks Research upgraded shares of Natera from a “strong sell” rating to a “hold” rating in a report on Thursday, January 1st. JPMorgan Chase & Co. lifted their price objective on Natera from $250.00 to $260.00 and gave the company an “overweight” rating in a research note on Monday, December 15th. Finally, UBS Group raised their price target on shares of Natera from $218.00 to $280.00 and gave the company a “buy” rating in a research report on Tuesday, November 18th. One analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $245.50.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.